The Role of ACE2 Receptors in the Pathogenesis of Covid-19

Zangini Nakazwe^1,

¹Department of Basic Sciences, University of Lusaka, P.O Box 36711, Lusaka, Zambia

Cite this paper:
Zangini Nakazwe. The Role of ACE2 Receptors in the Pathogenesis of Covid-19. Biomedicine and Biotechnology. 2024; 9(1):1-14. doi: 10.12691/bb-9-1-1

Abstract

The emergence of a novel pathogenic human Coronavirus first reported in China, December 2019 has attracted global attention and poses a public health concern. Scientific studies and advancements since Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) and Middle East Respiratory Syndrome (MERS) outbreaks have accelerated the understanding of the current Coronavirus disease-19 (Covid-19) pandemic especially in drug development. Here we explore the role of angiotensin converting enzyme-2 (ACE2); receptor for SARS-CoV-1 in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pathogenesis. ACE2 is found to be a functional receptor for SARS-CoV-2. The receptor binding domain structure of SARS-CoV-2 is similar to SARS-CoV-1 domain that interacts with ACE2. ACE2 is highly expressed in lung type II alveolar cells and infection with SARS-CoV-2 results in respiratory condition as reported in Covid-19 patients. It is highly expressed in other human organs including heart, kidneys, and the gastrointestinal tract, thereby posing high risk in Covid-19 infection and suggesting other alternative routes of transmission. The current study predicts that ACE2 allelic variants; rs73635825, rs1299103394, rs766996587, rs961360700, rs762890235, rs1396769231 have adverse impact on the encoded ACE2 possibly influencing resistance and susceptibility to Covid-19 infection, although no functional impact has been detected to date. Furthermore, use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers increases ACE2 expression levels with no associated risks in Covid-19 patients with comorbidities owing to the protective role of ACE2 in lung injury in animal disease models. The study results provide insight into the critical roles of ACE2 receptor and highlights potential targets for therapeutic interventions.

Keywords:
Covid-19 SARS-CoV-2 ACE2 receptors

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID- 19) outbreak. Journal of autoimmunity. 2020: 102433.
[2]	Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Journal of Clinical Medicine. 2020; 9(4): 1225.
[3]	Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4): 372.
[4]	Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020; 9(1): 221-36.
[5]	Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. Journal of medical virology. 2020; 92(5): 491-4.
[6]	Millet JK, Whittaker GR. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus research. 2015; 202: 120-34.
[7]	Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. Journal of autoimmunity. 2020: 102434.
[8]	Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral research. 2020:104792.
[9]	Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Advances in virus research. 81: Elsevier; 2011. p. 85-164.
[10]	Kuhn J, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cellular and molecular life sciences: CMLS. 2004; 61(21): 2738-43.
[11]	Liu M-Y, Zheng B, Zhang Y, Li J-P. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Diseases and Translational Medicine. 2020.
[12]	Alexandre J, Cracowski J-L, Richard V, Bouhanick B, editors. Renin-angiotensin-aldosterone system and COVID-19 infection. Annales d'Endocrinologie; 2020: Elsevier.
[13]	Cheng H, Wang Y, Wang GQ. Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. Journal of medical virology. 2020.
[14]	Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection. 2020.
[15]	Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807): 215-20.
[16]	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020; 395(10223): 497-506.
[17]	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020; 323(11): 1061-9.
[18]	Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020; 12(2): 244.
[19]	Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. American journal of respiratory and critical care medicine. 2020; 201(11): 1372-9.
[20]	Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020: 1-6.
[21]	Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020; 30(3): 269-71.
[22]	Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—preliminary report. New England Journal of Medicine. 2020.
[23]	Group RC. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New England Journal of Medicine. 2020.
[24]	Rentsch MB, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PloS one. 2011; 6(10): e25858.
[25]	Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020.
[26]	Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.
[27]	Othman H, Bouslama Z, Brandenburg J-T, Da Rocha J, Hamdi Y, Ghedira K, et al. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism. Biochemical and Biophysical Research Communications. 2020.
[28]	Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers of medicine. 2020: 1-8.
[29]	Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6): 1831-3. e3.
[30]	Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111(20): 2605-10.
[31]	Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. New England Journal of Medicine. 2020.
[32]	Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. Journal of virology. 2011; 85(9): 4122-34.
[33]	Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020; 94(7).
[34]	Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochemical and biophysical research communications. 2020.
[35]	Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. Journal of virology. 2019; 93(6).
[36]	Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, et al. Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein. Journal of medical virology. 2020.
[37]	Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensive care medicine experimental. 2015; 3(1): 1-17.
[38]	Madigan MT, Martinko, John M., Bender, Kelly S., Buckley, Daniel H., Stahl, David A. Brock Biology of Microorganisms 14th Edition2015. 819-22 p.
[39]	Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-t, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020.
[40]	Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M. Resistance to HIV infection. Journal of urban health. 2006; 83(1): 5-17.
[41]	Pinheiro DS, Santos RS, Jardim PCV, Silva EG, Reis AA, Pedrino GR, et al. The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PloS one. 2019; 14(8): e0221248.
[42]	Coutard B, Valle C, de Lamballerie X, Canard B, Seidah N, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral research. 2020; 176: 104742.
[43]	Kido H, Okumura Y, Takahashi E, Pan H-Y, Wang S, Yao D, et al. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2012; 1824(1): 186-94.
[44]	Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature medicine. 2005; 11(8): 875-9.
[45]	Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436(7047): 112-6.
[46]	Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New England Journal of Medicine. 2020; 382(17): 1653-9.
[47]	Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation research. 2020.
[48]	Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine. 2020; 8(4): e21.
[49]	Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018; 41(3): 513-21.
[50]	Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv. 2020.